Skip to content
DraconiticResearch
Search Sources API
197,785 studies31 sourcesUpdated 21 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies

  • Yang Liu1
  • Yu Liu2
  • Fawzi Abu Rous3
  • Bin Yang4
  • Stephane Champiat5
  • Maya Khalil6
  • Vaia Florou7
  • Yi-Long Wu8
  • Kai He9
  • Devalingam Mahalingam10
  • Yongsheng Li11
  • Pan Zheng12
22 more authors
  • Kun He13
  • Mingjia Li14
  • Tarek Mekhail15
  • Eric Schaefer16
  • Joshua Reuss17
  • Qitao Yu18
  • Meili Sun19
  • John Hamm20
  • Bilal Anouti21
  • Qing Wen22
  • Jin-Ji Yang23
  • Shiling Song24
  • Matthrew Gumbleton25
  • Zhi-hua Liu26
  • Luis Raez27
  • Cameron Pywell28
  • Huilin Wang29
  • Guru P Sonpavde30
  • Thomas J George31
  • Aline Fares31
  • Georgios Fotopoulos32
  • Kazuharu Kai24
32 affiliations
  1. 1Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  2. 2School of Public Health and Management, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
  3. 3Department of Internal Medicine, Michigan State University, East lansing, Michigan, USA
  4. 4Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China
  5. 5Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  6. 63University of Alabama at Birmingham, Birmingham, AL, USA
  7. 7Department of Haematology/Oncology, Internal Medicine, Jackson Memorial Hospital, Miami, Florida, USA
  8. 8Guangdong Lung Cancer Institute, Guangdong Provincial People`s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
  9. 9Department of Gastroenterology, Ren Ji Hospital, Punan Campus, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  10. 101Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
  11. 11School of Interdisciplinary Medicine and Engineering, Harbin Medical University, Harbin, Heilongjiang, People`s Republic of China
  12. 12OncoC4, Rockville, Maryland, USA
  13. 13Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China
  14. 14Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
  15. 156Advent Health Cancer Institute, Orlando, FL, USA
  16. 16The Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA
  17. 172Georgetown University, Washington, DC, USA
  18. 18Department of Respiratory Oncology, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China
  19. 19Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, China
  20. 20Department of Medical Oncology, Norton Cancer Institute, Louisville, Kentucky, USA
  21. 21The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  22. 22Department of Operating Theater, Ningbo Mingzhou Hospital, Ningbo, China
  23. 23Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China
  24. 24OncoC4, Inc., Rockville, MD, USA
  25. 25Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
  26. 26Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
  27. 27Memorial Health System, Pembroke Pines, FL, USA
  28. 28Novant Health, Winston Salem, NC, USA
  29. 29Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
  30. 30Advent Health Cancer Institute, Orlando, FL, USA
  31. 31University of Florida, Gainesville, FL, USA
  32. 32University of Texas Mays Cancer Center at San Antonio, San Antonio, TX, USA
Open at sourcePDFDOICite

Related

  1. Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.
    Changgon Kim, Youngil Koh, Youngwoo Jeon +4
    Annals of hematologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  2. Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies.
    Osama M Younis, Sencer Goklemez, Carmel Awadallah +19
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Fosfomycin monotherapy for the treatment of a complicated prostatic abscess caused by KPC-producing carbapenem-resistant Escherichia coli
    Nguyen Thi Tuyen, Nguyen Sy Thau, Pham Thi Thanh Nhan +2
    ASM case reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  4. MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
    Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger +24
    Nature MedicinePeer-reviewedCC BY-NC-NDFull text8 citedOncologyOpenAlex
  5. PD-1-based combination therapy versus monotherapy in relapsed or refractory classical Hodgkin lymphoma: a single-center retrospective cohort study
    Weiming Zhang, Nasha Yu, Qiang Ding +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref

Cite

BibTeXRIS
BibTeX
@article{liu20261187,
  title = {{1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies}},
  author = {Yang Liu and Yu Liu and Fawzi Abu Rous and Bin Yang and Stephane Champiat and Maya Khalil and Vaia Florou and Yi-Long Wu and Kai He and Devalingam Mahalingam and Yongsheng Li and Pan Zheng and Kun He and Mingjia Li and Tarek Mekhail and Eric Schaefer and Joshua Reuss and Qitao Yu and Meili Sun and John Hamm and Bilal Anouti and Qing Wen and Jin-Ji Yang and Shiling Song and Matthrew Gumbleton and Zhi-hua Liu and Luis Raez and Cameron Pywell and Huilin Wang and Guru P Sonpavde and Thomas J George and Aline Fares and Georgios Fotopoulos and Kazuharu Kai},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.1187},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.1187},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies
AU  - Yang Liu
AU  - Yu Liu
AU  - Fawzi Abu Rous
AU  - Bin Yang
AU  - Stephane Champiat
AU  - Maya Khalil
AU  - Vaia Florou
AU  - Yi-Long Wu
AU  - Kai He
AU  - Devalingam Mahalingam
AU  - Yongsheng Li
AU  - Pan Zheng
AU  - Kun He
AU  - Mingjia Li
AU  - Tarek Mekhail
AU  - Eric Schaefer
AU  - Joshua Reuss
AU  - Qitao Yu
AU  - Meili Sun
AU  - John Hamm
AU  - Bilal Anouti
AU  - Qing Wen
AU  - Jin-Ji Yang
AU  - Shiling Song
AU  - Matthrew Gumbleton
AU  - Zhi-hua Liu
AU  - Luis Raez
AU  - Cameron Pywell
AU  - Huilin Wang
AU  - Guru P Sonpavde
AU  - Thomas J George
AU  - Aline Fares
AU  - Georgios Fotopoulos
AU  - Kazuharu Kai
PY  - 2026
DA  - 2026/11/08
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.1187
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.1187
SN  - 2051-1426
ER  -